Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

被引：0
|
作者：
Ralf Gold
Ernst-Wilhelm Radue
Gavin Giovannoni
Krzysztof Selmaj
Eva Kubala Havrdova
Xavier Montalban
Dusan Stefoski
Till Sprenger
Randy R. Robinson
Sami Fam
Jonathan Smith
Spyros Chalkias
Giorgio Giannattasio
Gabriel Lima
Wanda Castro-Borrero
机构：
[1] St. Josef-Hospital/Ruhr-University Bochum,Medical Image Analysis Center
[2] University Hospital Basel,Barts and The London School of Medicine and Dentistry
[3] Queen Mary University of London,Department of Neurology
[4] University of Warmia and Mazury,Department of Neurology, First Faculty of Medicine
[5] Charles University,undefined
[6] Hospital Vall d’Hebron University,undefined
[7] Rush University Medical Center,undefined
[8] DKD Helios Klinik Wiesbaden,undefined
[9] AbbVie Inc.,undefined
[10] Biogen,undefined
[11] Biogen,undefined
来源：
Journal of Neurology | 2020年 / 267卷
关键词：
Daclizumab beta; Relapsing–remitting multiple sclerosis; SELECTED; Clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2851 / 2864
页数：13
相关论文
共 50 条
  • [1] Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
    Gold, Ralf
    Radue, Ernst-Wilhelm
    Giovannoni, Gavin
    Selmaj, Krzysztof
    Havrdova, Eva Kubala
    Montalban, Xavier
    Stefoski, Dusan
    Sprenger, Till
    Robinson, Randy R.
    Fam, Sami
    Smith, Jonathan
    Chalkias, Spyros
    Giannattasio, Giorgio
    Lima, Gabriel
    Castro-Borrero, Wanda
    JOURNAL OF NEUROLOGY, 2020, 267 (10) : 2851 - 2864
  • [2] Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
    Ralf Gold
    Ernst-Wilhelm Radue
    Gavin Giovannoni
    Krzysztof Selmaj
    Eva Havrdova
    Dusan Stefoski
    Till Sprenger
    Xavier Montalban
    Stanley Cohan
    Kimberly Umans
    Steven J. Greenberg
    Gulden Ozen
    Jacob Elkins
    BMC Neurology, 16
  • [3] Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
    Gold, Ralf
    Radue, Ernst-Wilhelm
    Giovannoni, Gavin
    Selmaj, Krzysztof
    Havrdova, Eva
    Stefoski, Dusan
    Sprenger, Till
    Montalban, Xavier
    Cohan, Stanley
    Umans, Kimberly
    Greenberg, Steven J.
    Ozen, Gulden
    Elkins, Jacob
    BMC NEUROLOGY, 2016, 16
  • [4] Safety and Efficacy of Long-Term Treatment With Daclizumab Beta: 6-Year Results From the SELECTED Extension Study
    Gold, Ralf
    Radue, Ernst-Wilhelm
    Giovannoni, Gavin
    Selmaj, Krzysztof
    Havrdova, Eva
    Montalban, Xavier
    Stefoski, Dusan
    Sprenger, Till
    Robinson, Randy R.
    Smith, Jonathan
    Parks, Becky
    Giannattasio, Giorgio
    Lima, Gabriel
    NEUROLOGY, 2018, 90
  • [5] Safety and efficacy of long-term treatment with daclizumab beta: 6-year results from the SELECTED extension study
    Gold, R.
    Radue, E-W.
    Giovannoni, G.
    Selmaj, K.
    Havrdova, E.
    Montalban, X.
    Stefoski, D.
    Sprenger, T.
    Robinson, R. R.
    Smith, J.
    Parks, B.
    Giannattasio, G.
    Eraly, S.
    Lima, G.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 897 - 898
  • [6] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Selmaj, K. W.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Janjua, A.
    Huang, V.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 548 - 549
  • [7] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, K.
    Hoogerheyde, J.
    Afsari, S.
    Sheffield, J. K.
    Shi, F.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 617 - 618
  • [8] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Krakovich, A.
    Sheffield, J. K.
    Cheng, C. -Y.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 359 - 360
  • [9] Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
    Kappos, Ludwig
    Cohan, Stanley
    Arnold, Douglas L.
    Robinson, Randy R.
    Holman, Joan
    Fam, Sami
    Parks, Becky
    Xiao, Shan
    Castro-Borrero, Wanda
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [10] The Safety and Efficacy of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis in the SELECTION Extension Study: Primary Results
    Giovannoni, Gavin
    Gold, Ralf
    Selmaj, Krzysztof
    Havrdova, Eva
    Montalban, Xavier
    Radue, Ernst-Wilhelm
    Stefoski, Dusan
    McNeill, Manjit
    Rana, Jitesh
    Elkins, Jacob
    O'Neill, Gilmore
    NEUROLOGY, 2013, 80
12345